In keeping with its growth strategy, FASTBASE has recently opened a 600K€ round of financing to incorporate new partners into the company. The round will be made through the Capital Cell platform (www.capitalcell.net), Europe’s first equity crowdfunding platform specialised in life sciences, with unique due diligence procedures.
This round, together with other 1M€+ non-dilutive funds and the strong customer traction that the company has already achieved, will allow us to boost our next three-year ambitious business development plan. Our mission is to improve patients´ lives and continue working on the launch of new and disruptive QF-Pro® biomarkers and assays, both with our current client partners as well as via the development of new exciting alliances. Should you be interested in participating, please do not hesitate to contact us at contact@fastbasesolutions.com.
